Canada's pCPA tiers spell out how far generic semaglutide prices will fall

Canada's drug-pricing system has laid out exactly how much cheaper generic semaglutide will get as more copies reach pharmacy shelves. Under the pan-Canadian Pharmaceutical Alliance (pCPA) framework, the first generic to launch is priced at 75% to 85% of the brand-name cost. A second generic drops that to about 50%. Once three or more generics are on the market, the price falls to 35% of brand.^[2]

Applied to today's Canadian prices, the math points to steep savings. Brand-name Ozempic currently runs from about C$86.40 to C$663 at Canadian pharmacies, while Wegovy ranges from C$270 to C$550, according to pricing tracked by GLP1Prices.ca.^[2] Mina Tadrous, a pharmacist and drug-policy researcher at the University of Toronto, told The BMJ that once three generics are selling, out-of-pocket costs should land around C$100 a month.^[2]

The pricing schedule is not a one-time deal that regulators negotiate product by product. It is automatic, triggered by how many competing generics have entered the market.^[2] Two generic semaglutide injections, from Dr. Reddy's Laboratories and Apotex, are already authorized by Health Canada, with Dr. Reddy's version available since mid-May 2026. Seven more generic applications remain under review.^[2]

The opening for generics traces back to a $C250 annual patent maintenance fee that Novo Nordisk stopped paying starting in 2018, combined with a separate regulatory exclusivity period that expired in January 2026.^[2] Novo Nordisk has not explained why it let the fee lapse, telling the BBC only that the Canadian situation reflects "specific patent timelines" and does not affect protections elsewhere.^[2] Patent expert Tahir Amin of the Initiative for Medicines, Access & Knowledge told the BBC the company could have extended the patent to 2028 but did not.^[2]

Why it matters for patients

This pricing shift applies to Canada, not the United States. Novo Nordisk's semaglutide patent remains intact in the U.S. until 2032, and in Europe and Japan until 2033, so American patients are not in line for a similar generic rollout on this timeline.^[2] For now, U.S. buyers who see reports of C$100 generic Ozempic in Canada should understand that price applies only to Canadian pharmacies operating under Canadian law, and Health Canada has separately warned about counterfeit and unauthorized GLP-1 products being sold by unlicensed retailers and online sellers.^[1]

The Canadian pricing tiers do offer a preview of what steep generic competition can do to GLP-1 costs once patents lapse or expire. Novo Nordisk's own financial guidance shows the scale of the pressure: the company forecast a 5% to 13% drop in 2026 sales as Canadian generics reached the market, and its share price fell 17% the day that guidance was announced.^[2] In response, Novo Nordisk has rolled out brand-name discount cards in Canada and an advertising campaign encouraging patients to ask for the brand product instead of a generic.^[2] Tadrous told The BMJ he expects the company to hold onto more market share than is typical after generic entry, in part because of that marketing push.^[2]

What happens next

Health Canada is still reviewing seven additional generic semaglutide applications beyond the two already authorized.^[2] Apotex has not announced a release date for its product. Once a third generic reaches Canadian pharmacies, the 35% pricing tier would take effect automatically under the pCPA framework, pushing costs toward the roughly C$100 monthly estimate cited by researchers.^[2] No comparable generic entry is expected in the U.S. market before Novo Nordisk's patent protections lapse there.